CD4 (81-92) (human)
CD4 (81-92) (human) is a fragment of hCD4. CD4 (81-92) (human) can undergo structural modifications including derivatization and cyclization to enhance antiviral potency and stability, with sequence alterations affecting its activity. CD4 (81-92) (human) is applicable to studies related to HIV-1 infection.
For research use only. We do not sell to patients.
- CAS No.: 126144-46-5
- Formula: C62H96N14O26S
- Molecular Weight:1485.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
HIV-1 |
Derivatized CD4 (81-92) (human) peptides exhibit concentration-dependent anti-HIV infection, anti-syncytium formation and viral inhibitory activities in CEM-SS, VB and H9 cells, with their potency varying by derivatization pattern; cyclized W3 displays submicromolar activity, and peptides #18, #30 and W3 can also block SIVSMM-B670 infection of CEM-174 cells[1].
CD4 (81-92) (human) benzylated peptide (7.8-125 μM; administered only 0-48 h post-inoculation) potently inhibits infection of CEM-SS cells by HIV-1 (HTLV-IIIB) and HIV-1 (RF-II) within the first 48 hours of infection[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 126144-46-5
-
Molecular Weight 1485.57
-
Formula C62H96N14O26S
-
SMILES
OC(C=C1)=CC=C1C[C@H](NC([C@@H](N)[C@H](O)C)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CS)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
-
Sequence
Thr-Tyr-Ile-Cys-Glu-Val-Glu-Asp-Gln-Lys-Glu-Glu
-
Sequence Shortening
TYICEVEDQKEE
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Rausch DM, et al. CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro. Biochem Pharmacol. 1992 Apr 15;43(8):1785-96. [Content Brief]
[2]. Lifson JD, et al. Synthetic peptides allow discrimination of structural features of CD4(81-92) important for HIV-1 infection versus HIV-1-induced syncytium formation. AIDS research and human retroviruses. 1991 Jun;7(6):521-7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CD4 (81-92) (human) Related Classifications
HY-P11802 Related Classifications
Powered by Bioz